Securities Times Newsamericanrouletteonline, at the 2024 ASCO Conferenceamericanrouletteonline, many domestic innovative pharmaceutical companies have released the latest research results of their clinical trials. Overall, the oncology drug forms of China's innovative pharmaceutical companies cover monoclonal antibodies, dual antibodies and ADCs. The product design is innovative and the clinical trial results are equally excellent, demonstrating good clinical effects in the treatment of various tumors.
CITIC Construction Investment Securities believes that China's innovative pharmaceutical companies continue to make efforts in the oncology track, and many products have shown the potential of BIC in oncology indications, and more subsequent clinical results are worthy of attention.
Proofread by: Zhu Tianting
